WO2019164010A1 - 膀胱がん用抗腫瘍剤および膀胱がんの処置方法 - Google Patents

膀胱がん用抗腫瘍剤および膀胱がんの処置方法 Download PDF

Info

Publication number
WO2019164010A1
WO2019164010A1 PCT/JP2019/007242 JP2019007242W WO2019164010A1 WO 2019164010 A1 WO2019164010 A1 WO 2019164010A1 JP 2019007242 W JP2019007242 W JP 2019007242W WO 2019164010 A1 WO2019164010 A1 WO 2019164010A1
Authority
WO
WIPO (PCT)
Prior art keywords
bladder cancer
antitumor agent
compound
salt
prodrug
Prior art date
Application number
PCT/JP2019/007242
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
フィリップ ジャンク
山田　孝之
Original Assignee
富士フイルム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士フイルム株式会社 filed Critical 富士フイルム株式会社
Publication of WO2019164010A1 publication Critical patent/WO2019164010A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the effect of treatment was determined according to the following criteria.
  • the evaluation object was confirmed by image diagnosis by MRI (nuclear magnetic resonance imaging), and judged according to the following criteria.
  • CR Complete Response
  • PR Partial Response
  • SD stable disease
  • PD progressive disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2019/007242 2018-02-26 2019-02-26 膀胱がん用抗腫瘍剤および膀胱がんの処置方法 WO2019164010A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862635269P 2018-02-26 2018-02-26
US62/635,269 2018-02-26

Publications (1)

Publication Number Publication Date
WO2019164010A1 true WO2019164010A1 (ja) 2019-08-29

Family

ID=67688200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/007242 WO2019164010A1 (ja) 2018-02-26 2019-02-26 膀胱がん用抗腫瘍剤および膀胱がんの処置方法

Country Status (2)

Country Link
TW (1) TW202000207A (zh)
WO (1) WO2019164010A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008511A1 (ja) 2021-07-29 2023-02-02 富士フイルム株式会社 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (fr) * 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (fr) * 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIURA, SHINJI ET AL.: "Antitumor activity of a novel orally effective nucleoside , 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine", CANCER LETTERS, vol. 129, 1998, pages 103 - 110, XP055213439, doi:10.1016/S0304-3835(98)00089-5 *
MIURA, SHINJI ET AL.: "Comparison of 1-(2-deoxy-2-fluoro-4-thio- beta -D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity", CANCER LETTERS, vol. 144, 1999, pages 177 - 182, XP055213437, doi:10.1016/S0304-3835(99)00221-9 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008511A1 (ja) 2021-07-29 2023-02-02 富士フイルム株式会社 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤
KR20240028451A (ko) 2021-07-29 2024-03-05 후지필름 가부시키가이샤 Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제

Also Published As

Publication number Publication date
TW202000207A (zh) 2020-01-01

Similar Documents

Publication Publication Date Title
CN101589026B (zh) 治疗脑神经胶质瘤的方法
JP2024063227A (ja) 肥満細胞症の治療のための併用療法
US20210267896A1 (en) Formulations for treating bladder cancer
KR102377742B1 (ko) 암치료약
WO2021063332A1 (zh) 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
EP3429582B1 (en) Combination therapy for proliferative diseases
WO2023092943A1 (zh) 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
JP2003523944A (ja) Ｐ−糖タンパク質修飾物質を用いる抗ウィルス療法
WO2018043530A1 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019176984A1 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019164010A1 (ja) 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
EP3429572A1 (en) Combination therapy for proliferative diseases
WO2016188399A1 (en) Pharmaceutical compositions and use thereof
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
WO2019146129A1 (ja) イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
JP4428481B2 (ja) 神経因性疼痛治療剤
TWI835050B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
WO2022199656A1 (zh) 药物组合、包含其的试剂盒及其用途
WO2019230595A1 (ja) びまん性胃癌の治療剤
CN114948951A (zh) Fk506或其可药用衍生物和铁死亡诱导剂联合在制备治疗癌症的药物中的用途
CN108358953A (zh) 铜与咪唑并吡啶类化合物的配合物及其应用
EP4378466A1 (en) Pharmaceutical composition and anti-tumor agent for tumors that have at least either impaired bap1 or pbrm1 function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19757867

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19757867

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP